Conjunctival melanoma with orbital invasion and liver metastasis managed with systemic immune checkpoint inhibitor therapy

Indian J Ophthalmol. 2019 Dec;67(12):2071-2073. doi: 10.4103/ijo.IJO_663_19.

Abstract

A 60-year-old Caucasian female was referred for biopsy-proven amelanotic orbito-conjunctival melanoma. Map biopsies revealed residual invasive melanoma on the deep tarsal margin at the site of previous surgery. Repeat excisions were required after recurrence was detected following 3 months and 7 months. Positron emission tomography scan detected liver metastasis and additional orbito-conjunctival melanoma recurrence. Biomarker testing showed NRAS mutation without BRAF or c-KIT mutations and without PD-L1 expression. Systemic checkpoint inhibitor therapy was initiated with regression of both the orbito-conjunctival melanoma and liver metastasis. Invasive, non resectable orbito-conjunctival melanoma with liver metastasis can demonstrate a response to systemic checkpoint inhibitor therapy.

Keywords: Checkpoint inhibitor; conjunctiva; eye; melanoma; tumor.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Conjunctival Neoplasms / diagnostic imaging
  • Conjunctival Neoplasms / drug therapy
  • Conjunctival Neoplasms / pathology*
  • Female
  • Humans
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary*
  • Magnetic Resonance Imaging
  • Melanoma / diagnostic imaging
  • Melanoma / drug therapy
  • Melanoma / secondary*
  • Middle Aged
  • Orbital Neoplasms / diagnostic imaging
  • Orbital Neoplasms / drug therapy
  • Orbital Neoplasms / secondary*
  • Positron-Emission Tomography

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • pembrolizumab